EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Neoadjuvant durvalumab and tremelimumab in combination with chemotherapy in newly diagnosed advanced high-grade serous ovarian cancer (iPRIME): a randomized, non-comparative phase 2 trial using chemotherapy response score as the primary endpoint

Tarek Meniawy, Janine Lombard, Catherine Shannon, Linda Mileshkin, Jeffrey Goh, Bo Gao, Kate Webber, Navin David Palayoor, Colin Stewart, Michael T. Fahey, Petra Opar, John Andrews und 3 weitere

Cancer Immunology, Immunotherapy · 31.10.2026

DOI: 10.1007/s00262-026-04589-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 31.10.2026. Verfasst von Tarek Meniawy und 14 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Astra.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Förderung

  • Astra

Zitieren

APA

Meniawy, T., Lombard, J., Shannon, C., Mileshkin, L., Goh, J., Gao, B., Webber, K., Palayoor, N. D., Stewart, C., Fahey, M. T., Opar, P., Andrews, J., Weatherall, K., Boo, M., & Friedlander, M. (2026). Neoadjuvant durvalumab and tremelimumab in combination with chemotherapy in newly diagnosed advanced high-grade serous ovarian cancer (iPRIME): a randomized, non-comparative phase 2 trial using chemotherapy response score as the primary endpoint. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04589-4

Vancouver

Meniawy T, Lombard J, Shannon C, Mileshkin L, Goh J, Gao B, et al. Neoadjuvant durvalumab and tremelimumab in combination with chemotherapy in newly diagnosed advanced high-grade serous ovarian cancer (iPRIME): a randomized, non-comparative phase 2 trial using chemotherapy response score as the primary endpoint. Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-026-04589-4

BibTeX
@article{Meniawy2026,
  author = {Meniawy, Tarek and Lombard, Janine and Shannon, Catherine and Mileshkin, Linda and Goh, Jeffrey and Gao, Bo and Webber, Kate and Palayoor, Navin David and Stewart, Colin and Fahey, Michael T. and Opar, Petra and Andrews, John and Weatherall, Kate and Boo, Marilyn and Friedlander, Michael},
  title = {Neoadjuvant durvalumab and tremelimumab in combination with chemotherapy in newly diagnosed advanced high-grade serous ovarian cancer (iPRIME): a randomized, non-comparative phase 2 trial using chemotherapy response score as the primary endpoint},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  doi = {10.1007/s00262-026-04589-4}
}
Kostenlos starten →